Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 1 institution in 1 country.
Biruk Sintayehu FantaDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0003-2122-3230
Jimma LenjisaDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Theodosia TeoDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Lianmeng KouDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Laychiluh MekonnenDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-7108-5345
Yuchao YangDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0002-1558-266X
Sunita K C BasnetDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Ramin HassankhaniDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Matthew J SykesDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0002-2509-5531
Mingfeng YuDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0002-0860-4816
Shudong WangDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-6225-5525
University of South Australia · AU
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Cyclin-dependent kinase 2 (CDK2) has been garnering considerable interest as a target to develop new cancer treatments and to ameliorate resistance to CDK4/6 inhibitors. However, a selective CDK2 inhibitor has yet to be clinically approved. With the desire to discover novel, potent, and selective CDK2 inhibitors, the phenylsulfonamide moiety of our previous lead compound
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.